Scleroderma Lung Disease (SLS)

Clinical Trial ID NCT00004563

PubWeight™ 12.76^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00004563

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.	Am J Respir Crit Care Med	2007	2.86
2	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.	Am J Respir Crit Care Med	2007	2.41
3	High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease.	Chest	2008	1.61
4	Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.	Chest	2012	1.44
5	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease.	Arthritis Rheum	2011	1.22
6	Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.	Chest	2009	1.12
7	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.	Ann Rheum Dis	2014	0.93
8	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.	Arthritis Res Ther	2015	0.86
9	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.	Ann Rheum Dis	2016	0.78